Navigation Links
Upsher-Smith Announces Development Agreement With Lundbeck
Date:9/30/2013

MAPLE GROVE, Minn., Sept. 30, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a fully integrated pharmaceutical company committed to the development of new treatments for diseases of the central nervous system, today announced that its UK subsidiary, Proximagen Limited, has entered into a preclinical development agreement with Denmark-based H. Lundbeck A/S (Lundbeck) to further its research program related to protein kinase inhibitors.  This transaction is part of Upsher-Smith's long-term strategy to advance its current product portfolio of branded drugs. Specific terms related to the deal have not been disclosed.

(Logo:  http://photos.prnewswire.com/prnh/20130520/NY17281LOGO )

"Upsher-Smith is pleased to announce today's development agreement with Lundbeck. We are very impressed with the world-class research conducted by Lundbeck and excited about the opportunity to bring a new therapy forward that may benefit patients," said Mark Evenstad, President and Chief Executive Officer of Upsher-Smith.

"Forming successful alliances is a key strategic objective for Lundbeck.  We share Upsher-Smith's commitment to develop therapies that may have the potential to improve the lives of people living with challenging medical conditions," said Ulf Wiinberg, Chief Executive Officer of Lundbeck.

About Upsher-Smith
Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded and generic pharmaceuticals.  Upsher-Smith has a particular focus on developing therapies to assist people suffering from central nervous system diseases, and also markets products relating to cardiology, dermatology, and women's health.  For more information, visit www.upsher-smith.com.

 


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
2. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
3. Upsher-Smith Is Honored with Prestigious Industry Award for Excellence and Innovation
4. Upsher-Smith Teams Up With Epilepsy Foundation of Minnesota for 2012 Stroll for Epilepsy
5. Tina Fehr, Senior Product Manager For AmLactin, Upsher-Smith Laboratories Named PM360 Trailblazer Winner For Womens Health Brand Manager
6. Doug Zitnak of Upsher-Smith Laboratories Named Small Brand Manufacturer Representative of the Year By Cardinal Health
7. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
8. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
9. Upsher-Smith Introduces Newly Redesigned Corporate Website
10. Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
11. Upsher-Smith Is Honored With Prestigious Industry Award For Leadership And Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. announced ... the 2016 Annual Meeting of the American Epilepsy Society ... is indicated as an adjunctive therapy for the treatment ... generalized seizures and primary generalized tonic-clonic seizures (PGTC) in ... and older. Please see Important Safety Information for FYCOMPA, ...
(Date:12/5/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... candidates, presents positive Phase 2a correlative data, as well as ... at the ongoing 58th American Society of Hematology (ASH) Annual ... . ... As previously announced, in ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... ... Will Never Be The Same” is a fictional tale about growing up with the ... the creation of published author, Kim T. Briggs, a self-described “big kid” who has ... and philosophy from Judson University in Elgin, Illinois. Having written numerous Christian drama skits ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... ability of physical therapist assistants, under direct supervision of a licensed physical therapist, ... physical therapy receives a consultation and treatment plan from a licensed physical therapist ...
(Date:12/5/2016)... IL (PRWEB) , ... December 05, 2016 , ... The ... to the individual looking to buy neoprene knee sleeves for lifting and ... The design focuses heavily on two main aspects to provide a higher quality knee ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... an excellent way to ensure moisture measurements are consistently correct. However, regular ... , Now, METTLER TOLEDO offers a solution: SmartCal™ . This ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... they have teamed up with The American College of Surgeons (ACS) to provide ... on Trauma, the “Bleeding Control Basic” course is a pilot program that fulfills ...
Breaking Medicine News(10 mins):